Latest On Sawai Pharmaceutical Co., Ltd (SWPIF):
About Sawai Pharmaceutical Co., Ltd (SWPIF):
Sawai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
General
- Name Sawai Pharmaceutical Co., Ltd
- Symbol SWPIF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 3,066
- Last Split Factor2:1
- Last Split Date2013-09-26
- Fiscal Year EndMarch
- Web URLhttp://www.sawai.co.jp
Valuation
- Trailing PE 10.98
- Forward PE 11.56
- Price/Sales (Trailing 12 Mt.) 1.25
- Price/Book (Most Recent Quarter) 1.06
- Enterprise Value Revenue 0.01
- Enterprise Value EBITDA 0.05
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 10%
- Return on Assets 4%
- Return on Equity 8%
- Revenue Per Share $0
- Gross Profit 73.5 billion
- Quarterly Earnings Growth 5.5%
Highlights
- Market Capitalization 2.17 billion
Share Statistics
- Shares Outstanding 43.79 million
- Shares Float 40.2 million
- % Held by Insiders 1129%
- % Held by Institutions 31.23%
Technicals
- Beta 0.38
- 52 Week High $52.81
- 52 Week Low $45.12
- 50 Day Moving Average 46.49
- 200 Day Moving Average 47.99
Dividends
- Forward Annual Dividend Rate $1.22
- Forward Annual Dividend Yield 2.52%
- Payout Ratio 2510%
- Dividend Date N/A
- ExDividend Date 2021-03-30
- Dividend Per Share $1.22
- Dividend Yield 0%
Sawai Pharmaceutical Co., Ltd (SWPIF) Dividend Calendar:
Sawai Pharmaceutical Co., Ltd pays out 2510% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Sawai Pharmaceutical Co., Ltd (SWPIF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2020-12-31 | $N/A | $1.44 | ||
2020-09-30 | 2020-12-31 | $46.23 billion | $1.46 | $108.78 | -98.66% |
2020-06-30 | 2020-09-30 | $N/A | $1.15 | $117.80 | -99.02% |
2020-03-31 | 2020-06-30 | $N/A | $1.16 | $72.69 | -98.41% |
2019-12-31 | 2020-03-31 | $49.79 billion | $0.42 | $143.91 | -99.71% |
2019-09-30 | 2019-12-31 | $43.35 billion | $1.33 | $140.80 | -99.05% |
2019-06-30 | 2019-09-30 | $47.13 billion | $0.96 | $121.07 | -99.21% |
2019-03-31 | 2019-06-30 | $46.34 billion | $1.36 | $43.35 | -96.86% |
2018-12-31 | 2019-03-31 | $49.21 billion | $0.53 | $114.23 | -99.54% |
2018-09-30 | 2018-12-31 | $43.49 billion | $1.31 | $76.36 | -98.29% |
2018-06-30 | 2018-09-30 | $45.3 billion | $1.06 | $86.82 | -98.78% |
2018-03-31 | 2018-06-30 | $51.53 billion | $1.08 | -$29.79 | 103.64% |
2017-12-31 | 2018-03-31 | $13.19 billion | -$0.01 | $110.42 | -100.01% |
2017-09-30 | 2017-12-31 | $37.11 billion | $1.23 | $82.54 | -98.52% |
2017-06-30 | 2017-09-30 | $33.65 billion | $1.00 | $113.92 | -99.13% |
2017-03-31 | 2017-06-30 | $31.05 billion | $1.12 | $99.12 | -98.87% |
2016-12-31 | 2017-03-31 | $35.96 billion | $0.54 | $144.25 | -99.62% |
2016-09-30 | 2016-12-31 | $1.19 | $104.60 | -98.86% | |
2016-06-30 | 2016-09-30 | $1.12 | $106.15 | -98.94% | |
2016-03-31 | 2016-06-30 | $1.15 | $55.34 | -97.92% | |
2015-12-31 | 2016-03-31 | $0.76 | $144.19 | -99.47% | |
2015-09-30 | 2015-12-31 | $1.24 | $84.73 | -98.53% | |
2015-06-30 | 2015-09-30 | $0.77 | $113.00 | -99.32% | |
2015-03-31 | 2015-06-30 | $1.13 | $51.70 | -97.81% | |
2014-12-31 | 2015-03-31 | $0.53 | |||
2014-09-30 | 2014-12-31 | $1.07 | |||
2014-06-30 | 2014-09-30 | $0.88 | |||
2014-03-31 | 2014-06-30 | $0.92 | |||
2013-12-31 | 2014-03-31 | $0.36 | |||
2013-09-30 | 2013-12-31 | $0.56 | |||
2013-06-30 | 2013-09-30 | $109.66 | |||
2013-03-31 | 2013-06-30 | $1.03 | |||
2012-12-31 | 2013-03-31 | $0.62 | |||
2012-09-30 | 2012-12-31 | $1.35 | |||
2012-06-30 | 2012-09-30 | $0.93 | |||
2012-03-31 | 2012-06-30 | $0.88 | |||
2011-12-31 | 2012-03-31 | $0.41 | |||
2011-09-30 | 2011-12-31 | $1.14 | |||
2011-06-30 | 2011-09-30 | $0.72 | |||
2011-03-31 | 2011-06-30 | $0.72 | |||
2010-12-31 | 2011-03-31 | $0.33 | |||
2010-09-30 | 2010-12-31 | $0.92 | |||
2010-06-30 | 2010-06-30 | $0.66 |
Sawai Pharmaceutical Co., Ltd (SWPIF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Research Development | N/A | 3.26 billion | N/A | N/A | 3.12 billion |
Income Before Tax | N/A | 7 billion | N/A | N/A | 8.63 billion |
Selling General Administrative | N/A | 8.09 billion | N/A | N/A | 8.26 billion |
Gross Profit | N/A | 18.45 billion | N/A | N/A | 19.91 billion |
Ebit | N/A | 11.76 billion | N/A | N/A | 8.69 billion |
Operating Income | N/A | 7.13 billion | N/A | N/A | 8.69 billion |
Income Tax Expense | 2.31 billion | 1.62 billion | 1.28 billion | 859 million | 2 billion |
Total Revenue | N/A | 46.23 billion | N/A | N/A | 49.79 billion |
Cost of Revenue | N/A | 27.79 billion | N/A | N/A | 29.88 billion |
Total Other Income Expense Net | N/A | N/A | N/A | N/A | -57 million |
Net Income From Continuing Operations | N/A | 5.38 billion | N/A | N/A | 6.64 billion |
Net Income Applicable to Common Shares | 6.59 billion | 5.33 billion | 5.47 billion | 1.96 billion | 6.35 billion |
Cash Flow:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Investments | -5.26 billion | N/A | N/A | N/A | N/A |
Change to Liabilities | 169 million | 188 million | -80 million | 295 million | -1.74 billion |
Total Cash Flow from Investing Activities | -5.26 billion | -3.33 billion | -2.69 billion | -2.87 billion | -8.89 billion |
Net Borrowings | -1.15 billion | 395 million | -2.84 billion | -1.12 billion | -1.24 billion |
Total Cash Flow from Financial Activities | N/A | N/A | N/A | -4.42 billion | -1.66 billion |
Change to Operating Activities | 265 million | -64 million | -2.8 billion | 2.32 billion | 1.22 billion |
Change in Cash | -1.23 billion | N/A | N/A | -5.17 billion | -1.37 billion |
Total Cash from Operating Activities | 5.78 billion | 7.66 billion | 13.12 billion | 1.98 billion | 9.09 billion |
Depreciation | 4.63 billion | N/A | N/A | 4.61 billion | 4.33 billion |
Other Cash Flow from Investing Activities | -381 million | -16 million | -12 million | 14 million | 551 million |
Change to Inventory | -2.07 billion | N/A | N/A | -890 million | -6.02 billion |
Change to Account Receivables | N/A | N/A | N/A | -10.3 billion | 5.7 billion |
Other Cash Flow from Financing Activities | -405 million | -643 million | -414 million | -452 million | -419 million |
Change to Net Income | 351 million | -4.01 billion | 527 million | -2.69 billion | -657 million |
Capital Expenditures | 4.88 billion | N/A | N/A | 850 million | 1.14 billion |
Balance Sheet:
Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | 150.58 billion | N/A | N/A | 154.92 billion |
Total Stockholder Equity | N/A | 215.28 billion | N/A | N/A | 209.35 billion |
Other Current Liabilities | 21.96 billion | 15.04 billion | N/A | N/A | 22.23 billion |
Total Assets | N/A | 388.97 billion | N/A | N/A | 388.23 billion |
Common Stock | 41.22 billion | 41.22 billion | 41.2 billion | 41.2 billion | 41.2 billion |
Other Current Assets | 1.46 billion | 1.73 billion | N/A | N/A | 972 million |
Retained Earnings | 138.42 billion | 134.67 billion | 129.34 billion | 126.72 billion | 124.76 billion |
Other Liabilities | 8.04 billion | 7.47 billion | 9.99 billion | 10.44 billion | 10.76 billion |
Other Assets | 4.27 billion | 4.41 billion | 4.4 billion | 5.51 billion | 4.77 billion |
Cash | N/A | 55.99 billion | N/A | N/A | 48.97 billion |
Total Current Liabilities | 75.68 billion | 84.46 billion | N/A | N/A | 82.55 billion |
Other Stockholder Equity | -4.26 billion | -2.11 billion | -173 million | 604 million | 1.92 billion |
Property, Plant & Equipment | 82.42 billion | 82.01 billion | 79.93 billion | 81.01 billion | 81.23 billion |
Total Current Assets | 203.03 billion | 199.02 billion | N/A | N/A | 192.34 billion |
Long Term Investments | N/A | N/A | N/A | N/A | 7.51 billion |
Net Tangible Assets | 122.74 billion | 118.81 billion | 113.19 billion | 109.7 billion | 106.97 billion |
Short Term Investments | N/A | 132 million | N/A | N/A | N/A |
Long Term Debt | N/A | 58.66 billion | N/A | N/A | 61.61 billion |
Inventory | 78.76 billion | 80.3 billion | N/A | N/A | 74.42 billion |
Accounts Payable | 48.28 billion | 46.51 billion | N/A | N/A | 44.07 billion |
Sawai Pharmaceutical Co., Ltd (SWPIF) Chart:
Sawai Pharmaceutical Co., Ltd (SWPIF) News:
Below you will find a list of latest news for Sawai Pharmaceutical Co., Ltd (SWPIF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sawai Pharmaceutical Co., Ltd (SWPIF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Sawai Pharmaceutical Co., Ltd (SWPIF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|